Goldman Sachs
PDLI

Goldman Sachs’s PDL BioPharma, Inc. PDLI Stock Holding History

Goldman Sachs’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-450,000
Closed -$954K – 7274
2016
Q4 		$954K Hold
450,000
– – ﹤0.01% 4501
2016
Q3 		$1.51M Buy
+450,000
New +$1.43M ﹤0.01% 4050
2016
Q2 		– Sell
-7,600
Closed -$25K – 7558
2016
Q1 		$25K Buy
7,600
+2,200
+41% +$6.86K ﹤0.01% 6691
2015
Q4 		$19K Sell
5,400
-324,900
-98% -$1.36M ﹤0.01% 6859
2015
Q3 		$1.66M Buy
330,300
+3,000
+0.9% +$17.2K ﹤0.01% 3986
2015
Q2 		$2.1M Buy
327,300
+65,900
+25% +$441K ﹤0.01% 3783
2015
Q1 		$1.84M Buy
261,400
+202,900
+347% +$1.47M ﹤0.01% 3871
2014
Q4 		$451K Buy
58,500
+48,700
+497% +$385K ﹤0.01% 5381
2014
Q3 		$73K Sell
9,800
-14,000
-59% -$130K ﹤0.01% 6714
2014
Q2 		$230K Sell
23,800
-2,800
-11% -$25K ﹤0.01% 6096
2014
Q1 		$221K Buy
26,600
+14,900
+127% +$128K ﹤0.01% 5998
2013
Q4 		$99K Sell
11,700
-13,800
-54% -$116K ﹤0.01% 6288
2013
Q3 		$203K Buy
25,500
+15,800
+163% +$127K ﹤0.01% 5862
2013
Q2 		$75K Buy
+9,700
New +$75.6K ﹤0.01% 5957

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Goldman Sachs's PDLI Position: Q4 2020 in Review

Goldman Sachs sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 141,731 shares — an estimated $446K sold.

Goldman Sachs first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $10.1M in Q4 2015. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Goldman Sachs reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Goldman Sachs sold 141,731 PDL BioPharma, Inc. shares in Q4 2020, an estimated $446K.
  • Goldman Sachs first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
  • Goldman Sachs's PDL BioPharma, Inc. position peaked at $10.1M in Q4 2015.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.